vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Zeta Global Holdings Corp. (ZETA). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $394.6M, roughly 1.8× Zeta Global Holdings Corp.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 1.7%, a 17.4% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 25.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $60.9M). Over the past eight quarters, Zeta Global Holdings Corp.'s revenue compounded faster (42.3% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Zeta Global Holdings Corp. is an American marketing technology company which was founded in 2007. Zeta offers companies a suite of multichannel marketing tools focused on creating, maintaining, and monetizing customer relationships. The company went public on the New York Stock Exchange on June 10, 2021, at a US$1.7 billion valuation.
MEDP vs ZETA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $394.6M |
| Net Profit | $135.1M | $6.5M |
| Gross Margin | — | 59.5% |
| Operating Margin | 21.6% | 4.5% |
| Net Margin | 19.1% | 1.7% |
| Revenue YoY | 32.0% | 25.4% |
| Net Profit YoY | 15.5% | -57.1% |
| EPS (diluted) | $4.65 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $394.6M | ||
| Q3 25 | $659.9M | $337.2M | ||
| Q2 25 | $603.3M | $308.4M | ||
| Q1 25 | $558.6M | $264.4M | ||
| Q4 24 | $536.6M | $314.7M | ||
| Q3 24 | $533.3M | $268.3M | ||
| Q2 24 | $528.1M | $227.8M | ||
| Q1 24 | $511.0M | $194.9M |
| Q4 25 | $135.1M | $6.5M | ||
| Q3 25 | $111.1M | $-3.6M | ||
| Q2 25 | $90.3M | $-12.8M | ||
| Q1 25 | $114.6M | $-21.6M | ||
| Q4 24 | $117.0M | $15.2M | ||
| Q3 24 | $96.4M | $-17.4M | ||
| Q2 24 | $88.4M | $-28.1M | ||
| Q1 24 | $102.6M | $-39.6M |
| Q4 25 | — | 59.5% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 62.1% | ||
| Q1 25 | — | 60.9% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.6% | ||
| Q2 24 | — | 60.0% | ||
| Q1 24 | — | 60.6% |
| Q4 25 | 21.6% | 4.5% | ||
| Q3 25 | 21.5% | 2.6% | ||
| Q2 25 | 20.9% | -1.7% | ||
| Q1 25 | 20.3% | -6.1% | ||
| Q4 24 | 23.4% | 2.2% | ||
| Q3 24 | 21.1% | -4.6% | ||
| Q2 24 | 19.9% | -11.7% | ||
| Q1 24 | 20.4% | -18.4% |
| Q4 25 | 19.1% | 1.7% | ||
| Q3 25 | 16.8% | -1.1% | ||
| Q2 25 | 15.0% | -4.2% | ||
| Q1 25 | 20.5% | -8.2% | ||
| Q4 24 | 21.8% | 4.8% | ||
| Q3 24 | 18.1% | -6.5% | ||
| Q2 24 | 16.7% | -12.3% | ||
| Q1 24 | 20.1% | -20.3% |
| Q4 25 | $4.65 | $0.04 | ||
| Q3 25 | $3.86 | $-0.02 | ||
| Q2 25 | $3.10 | $-0.06 | ||
| Q1 25 | $3.67 | $-0.10 | ||
| Q4 24 | $3.67 | $0.10 | ||
| Q3 24 | $3.01 | $-0.09 | ||
| Q2 24 | $2.75 | $-0.16 | ||
| Q1 24 | $3.20 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $319.8M |
| Total DebtLower is stronger | — | $197.1M |
| Stockholders' EquityBook value | $459.1M | $804.6M |
| Total Assets | $2.0B | $1.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $319.8M | ||
| Q3 25 | $285.4M | $385.2M | ||
| Q2 25 | $46.3M | $365.3M | ||
| Q1 25 | $441.4M | $364.4M | ||
| Q4 24 | $669.4M | $366.2M | ||
| Q3 24 | $656.9M | $418.5M | ||
| Q2 24 | $510.9M | $154.7M | ||
| Q1 24 | $407.0M | $141.6M |
| Q4 25 | — | $197.1M | ||
| Q3 25 | — | $196.9M | ||
| Q2 25 | — | $196.7M | ||
| Q1 25 | — | $196.5M | ||
| Q4 24 | — | $196.3M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | — | $184.4M | ||
| Q1 24 | — | $184.2M |
| Q4 25 | $459.1M | $804.6M | ||
| Q3 25 | $293.6M | $689.2M | ||
| Q2 25 | $172.4M | $673.3M | ||
| Q1 25 | $593.6M | $676.6M | ||
| Q4 24 | $825.5M | $676.8M | ||
| Q3 24 | $881.4M | $474.9M | ||
| Q2 24 | $763.6M | $217.0M | ||
| Q1 24 | $671.5M | $191.6M |
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.9B | $1.1B | ||
| Q4 24 | $2.1B | $1.1B | ||
| Q3 24 | $2.1B | $869.1M | ||
| Q2 24 | $1.9B | $583.9M | ||
| Q1 24 | $1.8B | $550.3M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.96× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $64.1M |
| Free Cash FlowOCF − Capex | $188.1M | $60.9M |
| FCF MarginFCF / Revenue | 26.6% | 15.4% |
| Capex IntensityCapex / Revenue | 0.6% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.43× | 9.81× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $185.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $64.1M | ||
| Q3 25 | $246.2M | $57.9M | ||
| Q2 25 | $148.5M | $42.0M | ||
| Q1 25 | $125.8M | $34.8M | ||
| Q4 24 | $190.7M | $43.7M | ||
| Q3 24 | $149.1M | $34.4M | ||
| Q2 24 | $116.4M | $31.1M | ||
| Q1 24 | $152.7M | $24.7M |
| Q4 25 | $188.1M | $60.9M | ||
| Q3 25 | $235.5M | $52.4M | ||
| Q2 25 | $142.4M | $39.7M | ||
| Q1 25 | $115.8M | $32.1M | ||
| Q4 24 | $183.0M | $35.4M | ||
| Q3 24 | $138.5M | $29.5M | ||
| Q2 24 | $103.5M | $24.4M | ||
| Q1 24 | $147.2M | $18.9M |
| Q4 25 | 26.6% | 15.4% | ||
| Q3 25 | 35.7% | 15.6% | ||
| Q2 25 | 23.6% | 12.9% | ||
| Q1 25 | 20.7% | 12.1% | ||
| Q4 24 | 34.1% | 11.3% | ||
| Q3 24 | 26.0% | 11.0% | ||
| Q2 24 | 19.6% | 10.7% | ||
| Q1 24 | 28.8% | 9.7% |
| Q4 25 | 0.6% | 0.8% | ||
| Q3 25 | 1.6% | 1.6% | ||
| Q2 25 | 1.0% | 0.8% | ||
| Q1 25 | 1.8% | 1.0% | ||
| Q4 24 | 1.4% | 2.6% | ||
| Q3 24 | 2.0% | 1.8% | ||
| Q2 24 | 2.4% | 3.0% | ||
| Q1 24 | 1.1% | 3.0% |
| Q4 25 | 1.43× | 9.81× | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | 2.87× | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
ZETA
Segment breakdown not available.
